AU2018298039B2 - Cell culture process for making a glycoprotein - Google Patents

Cell culture process for making a glycoprotein Download PDF

Info

Publication number
AU2018298039B2
AU2018298039B2 AU2018298039A AU2018298039A AU2018298039B2 AU 2018298039 B2 AU2018298039 B2 AU 2018298039B2 AU 2018298039 A AU2018298039 A AU 2018298039A AU 2018298039 A AU2018298039 A AU 2018298039A AU 2018298039 B2 AU2018298039 B2 AU 2018298039B2
Authority
AU
Australia
Prior art keywords
protein
glycan
ornithine
putrescine
soy hydrolysate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018298039A
Other languages
English (en)
Other versions
AU2018298039A1 (en
Inventor
Scott CARVER
John Chen
Ta-Chun HANG
Amy Johnson
Shawn Lawrence
Theodore LONEY
Ravindra PANGULE
Bernhard Schilling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2018298039A1 publication Critical patent/AU2018298039A1/en
Priority to AU2021229121A priority Critical patent/AU2021229121A1/en
Application granted granted Critical
Publication of AU2018298039B2 publication Critical patent/AU2018298039B2/en
Priority to AU2023202659A priority patent/AU2023202659B2/en
Priority to AU2025203053A priority patent/AU2025203053A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018298039A 2017-07-06 2018-07-03 Cell culture process for making a glycoprotein Active AU2018298039B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021229121A AU2021229121A1 (en) 2017-07-06 2021-09-06 Cell culture process for making a glycoprotein
AU2023202659A AU2023202659B2 (en) 2017-07-06 2023-05-01 Cell culture process for making a glycoprotein
AU2025203053A AU2025203053A1 (en) 2017-07-06 2025-04-30 Cell culture process for making a glycoprotein

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762529471P 2017-07-06 2017-07-06
US62/529,471 2017-07-06
US201862625744P 2018-02-02 2018-02-02
US62/625,744 2018-02-02
PCT/US2018/040734 WO2019010191A1 (en) 2017-07-06 2018-07-03 CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2021229121A Division AU2021229121A1 (en) 2017-07-06 2021-09-06 Cell culture process for making a glycoprotein
AU2023202659A Division AU2023202659B2 (en) 2017-07-06 2023-05-01 Cell culture process for making a glycoprotein

Publications (2)

Publication Number Publication Date
AU2018298039A1 AU2018298039A1 (en) 2020-01-16
AU2018298039B2 true AU2018298039B2 (en) 2023-02-02

Family

ID=64904487

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2018298039A Active AU2018298039B2 (en) 2017-07-06 2018-07-03 Cell culture process for making a glycoprotein
AU2021229121A Abandoned AU2021229121A1 (en) 2017-07-06 2021-09-06 Cell culture process for making a glycoprotein
AU2023202659A Active AU2023202659B2 (en) 2017-07-06 2023-05-01 Cell culture process for making a glycoprotein
AU2025203053A Pending AU2025203053A1 (en) 2017-07-06 2025-04-30 Cell culture process for making a glycoprotein

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021229121A Abandoned AU2021229121A1 (en) 2017-07-06 2021-09-06 Cell culture process for making a glycoprotein
AU2023202659A Active AU2023202659B2 (en) 2017-07-06 2023-05-01 Cell culture process for making a glycoprotein
AU2025203053A Pending AU2025203053A1 (en) 2017-07-06 2025-04-30 Cell culture process for making a glycoprotein

Country Status (13)

Country Link
US (5) US20190010531A1 (enExample)
EP (2) EP3967765A1 (enExample)
JP (5) JP7265494B2 (enExample)
KR (4) KR20210084695A (enExample)
CN (3) CN110914293B (enExample)
AU (4) AU2018298039B2 (enExample)
BR (1) BR112020000127A2 (enExample)
CA (1) CA3067847A1 (enExample)
IL (2) IL326217A (enExample)
MX (2) MX2020000228A (enExample)
SG (1) SG11201912548XA (enExample)
TW (2) TWI910092B (enExample)
WO (1) WO2019010191A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN113679744B (zh) * 2020-05-18 2023-12-29 中国人民解放军军事科学院军事医学研究院 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途
CN114058673A (zh) * 2021-09-15 2022-02-18 江苏先思达生物科技有限公司 一种脂肪肝检测试剂及其在脂肪肝检测中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045438A1 (en) * 2004-10-29 2006-05-04 Baxter International Inc. Animal protein-free media for cultivation of cells

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN1240300C (zh) * 2001-03-05 2006-02-08 科学与工业研究会 由大豆粉制备蛋白水解物的方法
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
US20060115901A1 (en) * 2004-10-22 2006-06-01 Bahram Valamehr Method and media for single cell serum-free culture of CHO cells
US7642078B2 (en) * 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
ES2474573T3 (es) * 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP5588865B2 (ja) 2007-07-31 2014-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｃｄ２０に対するヒト抗体及びその使用方法
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
NZ597727A (en) * 2009-07-31 2013-08-30 Baxter Int Cell culture medium for adamts protein expression
CN102115728B (zh) * 2009-12-31 2012-09-26 北京清大天一科技有限公司 无血清动物细胞培养基干粉、液体培养基及其制备方法
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
KR20130101034A (ko) * 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
KR20140097245A (ko) * 2011-10-31 2014-08-06 머크 샤프 앤드 돔 코포레이션 개선된 특성을 갖는 항체의 제조 방법
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
WO2013192009A1 (en) * 2012-06-21 2013-12-27 Baxter International Inc. Virus filtration of cell culture media
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
HK1206628A1 (en) * 2012-08-02 2016-01-15 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US20160237400A1 (en) * 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
CA2908407C (en) * 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
MX376230B (es) * 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
KR20170010003A (ko) * 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
MA40021A (fr) * 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045438A1 (en) * 2004-10-29 2006-05-04 Baxter International Inc. Animal protein-free media for cultivation of cells

Also Published As

Publication number Publication date
AU2021229121A1 (en) 2021-09-30
MX2020000228A (es) 2020-08-10
KR20250041082A (ko) 2025-03-25
JP7265494B2 (ja) 2023-04-26
KR20240055885A (ko) 2024-04-29
KR102782655B1 (ko) 2025-03-14
EP3649144A4 (en) 2021-07-21
AU2025203053A1 (en) 2025-05-22
TW202526028A (zh) 2025-07-01
CA3067847A1 (en) 2019-01-10
CN114075269A (zh) 2022-02-22
AU2021229121A2 (en) 2021-10-14
AU2023202659B2 (en) 2025-01-30
AU2018298039A1 (en) 2020-01-16
AU2023202659A1 (en) 2023-05-18
KR102659791B1 (ko) 2024-04-23
KR20200026248A (ko) 2020-03-10
CN110914293B (zh) 2024-08-13
JP7736872B2 (ja) 2025-09-09
JP7525672B2 (ja) 2024-07-30
EP3967765A1 (en) 2022-03-16
JP2025172879A (ja) 2025-11-26
CN118878651A (zh) 2024-11-01
CN110914293A (zh) 2020-03-24
SG11201912548XA (en) 2020-01-30
US20200131554A1 (en) 2020-04-30
AU2025203053A9 (en) 2026-03-05
US20210388408A1 (en) 2021-12-16
US20200255880A1 (en) 2020-08-13
MX2024013233A (es) 2024-12-06
JP2024138033A (ja) 2024-10-07
IL326217A (en) 2026-03-01
WO2019010191A1 (en) 2019-01-10
IL271524A (en) 2020-02-27
TW201934570A (zh) 2019-09-01
US20190010531A1 (en) 2019-01-10
JP2023052471A (ja) 2023-04-11
KR20210084695A (ko) 2021-07-07
US20210388407A1 (en) 2021-12-16
JP2021166537A (ja) 2021-10-21
BR112020000127A2 (pt) 2020-07-07
TWI910092B (zh) 2026-01-01
EP3649144A1 (en) 2020-05-13
JP2020526196A (ja) 2020-08-31

Similar Documents

Publication Publication Date Title
JP7736872B2 (ja) 糖タンパク質を作製するための細胞培養方法
ES2695169T3 (es) Métodos de cultivo de células
JP2024156901A (ja) 調節されたグリカンプロファイルを有する抗体
CA3165060C (en) Deglycosylation methods for electrophoresis of glycosylated proteins
EA053249B1 (ru) Процесс культивирования клеток для получения гликопротеина
EA042958B1 (ru) Процесс культивирования клеток для получения гликопротеина
BR122024025107A2 (pt) Métodos para produzir um anticorpo glicosilado em um meio de cultura celular, e para produzir um meio de cultura celular
Gupta Implementation of CQA (critical quality attribute) based approach for development of biosimilars

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)